Image Place holder

Michael A. Poch, MD


Specialty: Urology
Program: Genitourinary Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

A native of Connecticut, Dr. Poch entered Brown University as an undergraduate in the Program of Liberal Medical Education. He graduated with a BA in Biology from Brown University and went on to complete medical school at Brown Medical School. He stayed in Providence, Rhode Island at Brown University to complete his urology residency training. After residency he moved to Buffalo, New York to complete a Society for Urologic Oncology accredited urologic oncology fellowship at Roswell Park Cancer Institute. His clinical interests include bladder, kidney and prostate cancer with an emphasis on minimally invasive surgery and robotics. He is a reviewer for numerous professional journals, and is published in many peer-review­­­ed journals and has authored multiple book chapters on urologic oncology and robotics. He has lectured at national and international meetings. In addition, he currently sits on the National Comprehensive Cancer Network panel for prostate cancer early detection. Dr. Poch's research interests include health-related quality of life outcomes after oncologic surgery with a focus on post-operative body image and mental health assessments. Additional research interests include immunotherapy for bladder cancer, specifically evaluating the potential growth and expansion of tumor infiltrating lymphocytes. Dr. Poch is significantly involved in medical education at the University of South Florida and Moffitt Cancer Center. He is director of the Advanced Genitourinary Oncology elective for the medical school and is an integral part of the training for both the residents and Society for Urologic Oncology fellows.

Education & Training

Board Certification:

  • Urology

Fellowship:

  • Rosewell Park Cancer Institute - Urologic Oncology

Residency:

  • Rhode Island Hospital, Brown University - General Surgery and Urology

Medical School:

  • Alpert Medical School at Brown University - MD
Participating Trials

CLINICAL TRIAL 18787
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of Instiladrin (rAd-IFN/Syn3)Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer
Condition: Genitourinary
Intervention: INSTILADRIN
Open

CLINICAL TRIAL 17753
Focal Prostate Radio-Frequency Ablation for the Treatment of Prostate Cancer
Condition: Genitourinary
Intervention:
Open

CLINICAL TRIAL 18523
A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men with Prostate Cancer (VANDAAM Study)
Condition: Genitourinary
Intervention: Not Applicable
Open

CLINICAL TRIAL 18680
A study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer
Condition: Genitourinary
Intervention: ALT-803; BCG
Open

CLINICAL TRIAL 18788
A Phase 2 Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Condition: Genitourinary
Intervention: AMP-514 (Durvalumab); Durvalumab; MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18536
Coordinated High Dose Interleukin-2 (aldesleukin, Proleukin) and Pembrolizumab (anti-PD1, Keytruda) for Therapy of Metastatic Kidney Cancer
Condition: Genitourinary
Intervention: IL-2 (Interleukin-2); Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18201
A Phase I Dose Escalation Study of Preoperative Stereotactic Body Radiation Therapy (SBRT) for High Risk Prostate Cancer
Condition: Genitourinary
Intervention: Not Applicable
Open

CLINICAL TRIAL 18980
A Phase III, Multicenter, Randomized,Placebo-Controlled, Double-Blind Study of Atezolizumab (AntiPd-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Condition: Genitourinary
Intervention: Atezolizumab (Tecentriq); Placebo
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival. Urology. 2017 May;103:142-148. Pubmedid: 28011275.
  • Chipollini JJ, Tang DH, Patel SY, Garcia-Getting RE, Gilbert SM, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA. Author Reply. Urology. 2017 May;103:148. Pubmedid: 28108090.
  • Tang DH, Nawlo J, Chipollini J, Gilbert SM, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?. Clin Genitourin Cancer. 2017 May. Pubmedid: 28566202.
  • Chipollini J, Tang DH, Gilbert SM, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE. Delay to Inguinal Lymph Node Dissection Greater than 3 months Predicts Poorer Recurrence Free Survival for Penile Cancer Patients. J Urol. 2017 Jun. Pubmedid: 28652123.
  • Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center. Urology. 2017 Jul;105:108-112. Pubmedid: 28342928.
  • Leone AR, Zargar-Shoshtari K, Diorio GJ, Sharma P, Boulware D, Gilbert SM, Powsang JM, Zhang J, Sexton WJ, Spiess PE, Poch MA. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience. Clin Genitourin Cancer. 2017 Aug;15(4):e583-e589. Pubmedid: 28410909.
  • Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Surgical control and margin status after robotic and open cystectomy in high-risk cases: Caution or equivalence?. World J Urol. 2017 Apr;35(4):657-663. Pubmedid: 27495912.
  • Zargar-Shoshtari K, Sexton WJ, Poch MA. Management of Urethral Recurrences: Urothelial and Nonurothelial. Urol Clin North Am. 2016 Nov;43(4):515-521. Pubmedid: 27717437.
  • Zargar-Shoshtari K, Kongnyuy M, Sharma P, Fishman MN, Gilbert SM, Poch MA, Pow-Sang JM, Spiess PE, Zhang J, Sexton WJ. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy. World J Urol. 2016 Nov;34(11):1567-1573. Pubmedid: 27072536.
  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Ne. 2016 May;14(5):509-519. Pubmedid: 27160230.
  • Luchey AM, Manimala NJ, Dickinson S, Dhillon J, Agarwal G, Lockhart JL, Spiess PE, Sexton WJ, Pow-Sang JM, Gilbert SM, Poch MA. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology. 2016 Jul;93:130-134. Pubmedid: 27041469.
  • Sharma P, Henriksen CH, Zargar-Shoshtari K, Xin R, Poch MA, Pow-Sang JM, Sexton WJ, Spiess PE, Gilbert SM. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy. J Urol. 2016 Jan;195(1):47-52. Pubmedid: 26235376. Pmcid: PMC4924593.
  • Lue K, Russell CM, Fisher J, Kurian T, Agarwal G, Luchey A, Poch M, Pow-Sang JM, Sexton WJ, Spiess PE. Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis. Clin Genitourin Cancer. 2016 Feb;14(1):89-95. Pubmedid: 26453395.
  • Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation. Clin Genitourin Cancer. 2016 Feb;14(1):82-88. Pubmedid: 26411593.
  • Russell CM, Sharma P, Agarwal G, Fisher JS, Richard GJ, Spiess PE, Pow-Sang JM, Poch MA, Sexton WJ. Is percent seminoma associated with intraoperative morbidity during post-chemotherapy RPLND?. Can J Urol. 2016 Feb;23(1):8127-8134. Pubmedid: 26892052.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Richard GJ, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015 Oct;33(10):1585-1592. Pubmedid: 25552207.
  • Luchey AM, Agarwal G, Espiritu PN, Lockhart JL, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA. Patient and disease-specific factors and their influence on urinary reconstruction choice at a referral center. World J Urol. 2015 Nov;33(11):1763-1768. Pubmedid: 25774005.
  • Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for Bladder Urothelial Cancer. J Urol. 2015 Nov;194(5):1220-1225. Pubmedid: 26055823.
  • Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun;13(3):225-230. Pubmedid: 25544725.
  • Luchey AM, Agarwal G, Poch MA. Robotic-Assisted Radical Cystectomy. Cancer Control. 2015 Jul;22(3):301-306. Pubmedid: 26351885.
  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Ne. 2015 Dec;13(12):1534-1561. Pubmedid: 26656522.
  • Emtage JB, Poch MA, Hutton MT, Emtage JB. Prostate cancer trends in Barbados: An analysis of the Barbados Urologic Diseases Survey database. Cancer Epidemiol. 2015 Dec;39(6):825-830. Pubmedid: 26651441.
  • Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, Sexton WJ, Spiess PE. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015 Aug;33(8):339.e17-339.e23. Pubmedid: 26094169.
  • Gopman JM, Djajadiningrat RS, Baumgarten AS, Espiritu PN, Horenblas S, Zhu Y, Protzel C, Pow-Sang JM, Kim T, Sexton WJ, Poch MA, Spiess PE. Predicting postoperative complications of inguinal lymph node dissection for penile cancer in an international multicentre cohort. BJU Int. 2015 Aug;116(2):196-201. Pubmedid: 25777366.
  • Sharma P, Sverrisson EF, Zargar-Shoshtari K, Fishman MN, Sexton WJ, Dickinson SI, Spiess PE, Poch MA, Gilbert SM, Pow-Sang JM. Minimally invasive post-chemotherapy retroperitoneal lymph node dissection for nonseminoma. Can J Urol. 2015 Aug;22(4):7882-7889. Pubmedid: 26267026.
  • Zargar-Shoshtari K, Kim T, Simon R, Lin HY, Yue B, Sharma P, Spiess PE, Poch MA, Pow Sang J, Sexton WJ. Surveillance Following Nephron-Sparing Surgery: An Assessment of Recurrence Patterns and Surveillance Costs. Urology. 2015 Aug;86(2):321-326. Pubmedid: 26187013.
  • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Ne. 2014 Sep;12(9):1211-1219. Pubmedid: 25190691.
  • Espiritu PN, Sverrisson EF, Sexton WJ, Pow-Sang JM, Poch MA, Dhillon J, Spiess PE. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection. Urol Oncol. 2014 Jul;32(5):619-624. Pubmedid: 24495448.
  • Poch MA, Stegemann AP, Rehman S, Sharif MA, Hussain A, Consiglio JD, Wilding GE, Guru KA. Short-term patient reported health-related quality of life (HRQL) outcomes after robot-assisted radical cystectomy (RARC). BJU Int. 2014 Feb;113(2):260-265. Pubmedid: 23773798.
  • Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE. Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. J Urol. 2014 Aug;192(2):350-356. Pubmedid: 24530987.
  • Strom TJ, Wilder RB, Fernandez DC, Mellon EA, Saini AS, Hunt DC, Pow-Sang JM, Spiess PE, Sexton WJ, Poch MA, Biagioli MC. A dosimetric study of polyethylene glycol hydrogel in 200 prostate cancer patients treated with high-dose rate brachytherapy±intensity modulated radiation therapy. Radiother Oncol. 2014 Apr;111(1):126-131. Pubmedid: 24746567.
  • Poch MA, Mehedint D, Green DJ, Payne-Ondracek R, Fontham ET, Bensen JT, Attwood K, Wilding GE, Guru KA, Underwood W, Mohler JL, Heemers HV. The association between calcium channel blocker use and prostate cancer outcome. Prostate. 2013 Jun;73(8):865-872. Pubmedid: 23280547.
  • Poch MA, Raza J, Nyquist J, Guru KA. Tips and tricks to robot-assisted radical cystectomy and intracorporeal diversion. Curr Opin Urol. 2013 Jan;23(1):65-71. Pubmedid: 23202288.
  • Rao AR, Stegemann AP, Rehman S, Poch MA, Green D, Guru KA. Status of Robot-Assisted Radical Cystectomy (RARC) in 2012. Indian J Surg Oncol. 2012 Jun;3(2):85-90. Pubmedid: 23730095. Pmcid: PMC3392479.
  • Poch MA, Stegemann A, Chandrasekhar R, Hayn M, Wilding G, Guru KA. Does body mass index impact the performance of robot-assisted intracorporeal ileal conduit?. J Endourol. 2012 Jul;26(7):857-860. Pubmedid: 22332715.
  • Sharma P, Zargar-Shoshtari K, Spiess PE, Sexton WJ, Poch MA. Undiagnosed prostatic malignancy at the time of radical cystoprostatectomy after prior prostatic radiation therapy. Urol Ann. 8(2):151-156. Pubmedid: 27141183. Pmcid: PMC4839230.